ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

COG Cambridge Cognition Holdings Plc

52.00
0.00 (0.00%)
Last Updated: 08:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 52.00 51.00 53.00 52.00 52.00 52.00 3,300 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 12.61M -409k -0.0117 -44.44 18.12M
Cambridge Cognition Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker COG. The last closing price for Cambridge Cognition was 52p. Over the last year, Cambridge Cognition shares have traded in a share price range of 48.80p to 104.00p.

Cambridge Cognition currently has 34,852,833 shares in issue. The market capitalisation of Cambridge Cognition is £18.12 million. Cambridge Cognition has a price to earnings ratio (PE ratio) of -44.44.

Cambridge Cognition Share Discussion Threads

Showing 251 to 274 of 875 messages
Chat Pages: Latest  11  10  9  8  7  6  5  4  3  2  1
DateSubjectAuthorDiscuss
07/6/2017
09:45
FinnCap restated their corporate rating on shares of Cambridge Cognition Holdings PLC (LON:COG) in a research note published on Tuesday morning. They currently have a GBX 130 ($1.67) price objective on the stock.
jamesd888
07/6/2017
09:38
Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')


Speech recognition for clinical trials



Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG, 'Company'), the neuroscience digital health company, is pleased to announce its application of automatic speech recognition ("ASR") technology to develop new products to enable scalable, language-based clinical assessment to reduce clinical trial variability and costs and increase overall clinical trial efficiency.

The Company is now employing commercially available Artificial Intelligence ("AI") and ASR technologies to make language-based verbal cognitive assessments that are scalable, automated and consistent, which in turn will reduce human error between trial centres and between trial subjects. The first products are expected to be available commercially in mid 2018.

Language is a unique human capability that exhibits measurable changes in many psychiatric and neurological conditions including Alzheimer's disease, depression and schizophrenia. To date it has been difficult for clinical researchers to perform language-based assessments or measure verbal cognitive changes without highly trained experts. Now this new combination of speech recognition technology with Cambridge Cognition's validated computerised tests will make this possible.

This new platform, powered by AI, will allow innovative types of language-based cognitive assessment raising the possibility of delivering clinician-administered cognitive testing remotely and directly into people's homes for health assessments and trial subject profiling and triaging. The company also sees future opportunities to provide a means of monitoring well-established clinical interactions objectively for quality control, which will reduce reliance on human raters. This could have a significant impact on trial cost and speed of recruitment.

The Company's ASR-based technology will be unveiled formally at the Alzheimer's Association Technology and Dementia preconference in London on July 15 2017, where data from a proof of concept study will be presented.

jamesd888
07/6/2017
09:15
Up 5 percent now....hold on to your hats
jamesd888
07/6/2017
08:58
Great RNS today
jamesd888
07/6/2017
08:52
Expect this COG to grow rapidly this year
jamesd888
30/5/2017
16:11
Wrong thread?
oliversanvil
30/5/2017
15:32
Punters charging for the exits.
Always best to sell these illiquid tiddlers when they are tipped and buy back when the euphoria has abated.

phowdo
22/5/2017
09:25
mental health treatment set to double...expect COG to be £9.00 by the end of the year....the next move upwards will be pretty fast...buy now before this blows
jamesd888
10/5/2017
10:51
up 1% now.....are we gonna close around 1.50 today
jamesd888
10/5/2017
09:49
Company looking after employees...Well worth buying
jamesd888
09/5/2017
10:05
This is going heading over £2.00 and once they get FDA this will fly to £4.00 news expected very soon
jamesd888
05/5/2017
16:26
Cognition Kit deal...looking forward to Monday
jamesd888
05/5/2017
15:59
This is under the radar and about to fly
jamesd888
05/5/2017
15:58
looking forward to next week
jamesd888
05/5/2017
15:37
COG new contract deal....hold on to your hats...news not out....could hit £2.00 soon
jamesd888
21/4/2017
10:12
Apologies. COG is listed in today's issue as one of Simon Thompson's recent articles (page 15), but it seems his very full analysis remains for internet subscribers only. For now anyway.
hew
20/4/2017
16:17
Will be on newsagent's shelves on Friday.
hew
19/4/2017
23:42
That wouldn't be fair to paying subscribers

it's only around £28 per quarter to sign up

spob
19/4/2017
15:07
Come guys and gals somebody post the article please
pgaffney
19/4/2017
13:16
anyone able to share a synopsis of at what he said
janeann
19/4/2017
12:39
The Simon Thompson (IC) effect
gersemi
19/4/2017
12:21
i'm only going on the past with these, spikes often give way to selling. only my opinion...
targatarga
19/4/2017
12:17
thanks.......
janeann
19/4/2017
12:15
just dumped my 25k at 102, tipped in ic apparently.
targatarga
Chat Pages: Latest  11  10  9  8  7  6  5  4  3  2  1

Your Recent History

Delayed Upgrade Clock